At Gertrude Biomedical, we target the genes that build blood & lymphatic vessels by blocking the activity of the SOX18 transcription factor. This approach 'short circuits' the gene programs that promote pathological vessels in disease.
SOX18 is a transcription factor, that turns 'on' the genes that are important in vascular development. The unchecked formation of new vessels drives cancer growth and spread (metastasis). ‘Switching off’ SOX18 activity to restrict vascular growth, therefore, is a critical step in targeting diseases that depend on vessels for tumour growth or metastases.